Sign In
Buy MCRB
$4.83
+0.0500 (+1.05%)
At Close: Jul 31, 2026
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Tuesday, 19'th Mar 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on March 13, 2024, the Co
Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript
03:33pm, Tuesday, 05'th Mar 2024
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2023 Earnings Call Transcript March 5, 2024 8:30 AM ET Company Participants Rob Windsor - IR Eric Shaff - CEO Terri Young - CCO & CSO Lisa von Moltke - CMO D
Gold Price Alert: Gold Spot Prices Just Hit a Record High Today
10:18am, Tuesday, 05'th Mar 2024
Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally yesterday. The increasing price of gold is catching up to its c
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
07:00am, Tuesday, 05'th Mar 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided b
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
07:00am, Wednesday, 28'th Feb 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcas
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
07:00am, Tuesday, 27'th Feb 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres T
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
07:00am, Monday, 26'th Feb 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Ch
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Wednesday, 17'th Jan 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 10, 2024, the
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
07:00am, Tuesday, 09'th Jan 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
04:00pm, Thursday, 04'th Jan 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th
Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript
11:52am, Saturday, 04'th Nov 2023
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Kevin Mannix - Head, IR Eric Shaff - CEO Dr. Terri Young - Chief Commercial Off
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
07:00am, Thursday, 02'nd Nov 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported financial results for the third quarter ended September 30, 2023,
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thur
